Scholarlink

Purpose <p>Endocrine immune-related adverse events (irAEs) are increasingly encountered with immune checkpoint inhibitors (ICIs), yet patterns of screening, referral, and emergency outcomes remain underexplored. This study evaluated the adequacy of endocrine monitoring, iming of endocrinology involvement, and determinants of endocrine emergencies in ICI-treated patients.</p> Methods <p>We retrospectively reviewed 103 patients (67 men, 36 women; mean age 60.8 ± 12.1 years) referred to the Endocrinology Department between 2016 and 2025. Clinical data, cancer types, immunotherapy regimens, hormonal assessments, and causes and timing of referral were analyzed.</p> Results <p>Most patients (93.3%) were referred due to newly developed endocrine irAEs, with endocrinology involvement occurring at a median of 7.4 months (≈ 10th therapy cycle) after ICI initiation. The predominant ICI regimen involved PD-1 inhibitors (66%). Thyroid dysfunction (<i>n</i> = 64), secondary adrenal insufficiency (<i>n</i> = 28), and hyperglycemia (<i>n</i> = 4) were the leading endocrinopathies; hypophysitis was detected in 7 cases. Before ICI treatment, endocrine evaluation was absent in 22.3% and incomplete in 38.2%, while 9.7% received no endocrine follow-up during ICI therapy. Emergency admissions occurred in 17.4%, mainly due to adrenal crisis (<i>n</i> = 12), followed by thyrotoxicosis (<i>n</i> = 3). Although baseline screening status and timing of endocrinology involvement were not associated with emergency risk, phenotype strongly influenced outcomes: central adrenal insufficiency increased risk (RR = 3.29; 95% CI 1.33–8.08; <i>p</i> = 0.0197).</p> Conclusions <p>Endocrine irAEs are frequent and may be recognized only after clinical deterioration, exposing patients to preventable endocrine emergencies, particularly adrenal crisis. These findings highlight heterogeneity and gaps in endocrine surveillance during ICI therapy and support early, structured oncologist–endocrinologist collaboration with standardized baseline and follow-up assessments to improve patient safety and continuity of immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Heterogeneity in endocrine monitoring and timing of endocrinology involvement during immune checkpoint inhibitor therapy: A Real-World Single-Center study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Selin Tekin,
  • Seda Hanife Oguz,
  • Süleyman Nahit Sendur,
  • Ugur Ünlütürk,
  • Tomris Erbas,
  • Selcuk Dagdelen

摘要

Purpose

Endocrine immune-related adverse events (irAEs) are increasingly encountered with immune checkpoint inhibitors (ICIs), yet patterns of screening, referral, and emergency outcomes remain underexplored. This study evaluated the adequacy of endocrine monitoring, iming of endocrinology involvement, and determinants of endocrine emergencies in ICI-treated patients.

Methods

We retrospectively reviewed 103 patients (67 men, 36 women; mean age 60.8 ± 12.1 years) referred to the Endocrinology Department between 2016 and 2025. Clinical data, cancer types, immunotherapy regimens, hormonal assessments, and causes and timing of referral were analyzed.

Results

Most patients (93.3%) were referred due to newly developed endocrine irAEs, with endocrinology involvement occurring at a median of 7.4 months (≈ 10th therapy cycle) after ICI initiation. The predominant ICI regimen involved PD-1 inhibitors (66%). Thyroid dysfunction (n = 64), secondary adrenal insufficiency (n = 28), and hyperglycemia (n = 4) were the leading endocrinopathies; hypophysitis was detected in 7 cases. Before ICI treatment, endocrine evaluation was absent in 22.3% and incomplete in 38.2%, while 9.7% received no endocrine follow-up during ICI therapy. Emergency admissions occurred in 17.4%, mainly due to adrenal crisis (n = 12), followed by thyrotoxicosis (n = 3). Although baseline screening status and timing of endocrinology involvement were not associated with emergency risk, phenotype strongly influenced outcomes: central adrenal insufficiency increased risk (RR = 3.29; 95% CI 1.33–8.08; p = 0.0197).

Conclusions

Endocrine irAEs are frequent and may be recognized only after clinical deterioration, exposing patients to preventable endocrine emergencies, particularly adrenal crisis. These findings highlight heterogeneity and gaps in endocrine surveillance during ICI therapy and support early, structured oncologist–endocrinologist collaboration with standardized baseline and follow-up assessments to improve patient safety and continuity of immunotherapy.